Analysis of the different subpeptidomes presented by the HLA class I molecules of the B7 supertype

IF 3.7 4区医学 Q2 CELL BIOLOGY

Cellular immunology Pub Date : 2023-05-01 DOI:10.1016/j.cellimm.2023.104707

Adrián Tirado-Herranz , Pablo Guasp , Alba Pastor-Moreno , María Area-Navarro , Iñaki Alvarez

{"title":"Analysis of the different subpeptidomes presented by the HLA class I molecules of the B7 supertype","authors":"Adrián Tirado-Herranz , Pablo Guasp , Alba Pastor-Moreno , María Area-Navarro , Iñaki Alvarez","doi":"10.1016/j.cellimm.2023.104707","DOIUrl":null,"url":null,"abstract":"<div>MHC-I molecules of the HLA-B7 supertype preferentially bind peptides with proline at position 2. HLA-B*51:01 and B*51:08 present two predominant subpeptidomes, one with Pro2 and hydrophobic residues at P1, and another with Ala2 and Asp enriched at position 1. Here, we present a meta-analysis of the peptidomes presented by molecules of the B7 supertype to investigate the presence of subpeptidomes across different allotypes. Several allotypes presented subpeptidomes differing in the presence of Pro or another residue at P2. The Ala2 subpeptidomes preferred Asp1 except in HLA-B*54:01, where ligands with Ala2 contained Glu1. Sequence alignment and the analysis of crystal structures allowed us to propose positions 45 and 67 of the MHC heavy chain as relevant for the presence of subpeptidomes. Deciphering the principles behind the presence of subpeptidomes could improve our understanding of antigen presentation in other MHC-I molecules.Running title: HLA-B7 supertype subpeptidomes.</div>","PeriodicalId":9795,"journal":{"name":"Cellular immunology","volume":"387 ","pages":"Article 104707"},"PeriodicalIF":3.7000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337693/pdf/nihms-1910168.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0008874923000461","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

MHC-I molecules of the HLA-B7 supertype preferentially bind peptides with proline at position 2. HLA-B*51:01 and B*51:08 present two predominant subpeptidomes, one with Pro2 and hydrophobic residues at P1, and another with Ala2 and Asp enriched at position 1. Here, we present a meta-analysis of the peptidomes presented by molecules of the B7 supertype to investigate the presence of subpeptidomes across different allotypes. Several allotypes presented subpeptidomes differing in the presence of Pro or another residue at P2. The Ala2 subpeptidomes preferred Asp1 except in HLA-B*54:01, where ligands with Ala2 contained Glu1. Sequence alignment and the analysis of crystal structures allowed us to propose positions 45 and 67 of the MHC heavy chain as relevant for the presence of subpeptidomes. Deciphering the principles behind the presence of subpeptidomes could improve our understanding of antigen presentation in other MHC-I molecules.

Running title: HLA-B7 supertype subpeptidomes.

查看原文本刊更多论文

B7超型HLA I类分子不同亚感受区的分析

HLA-B7超型的MHC-I分子优先在2位与脯氨酸结合肽。HLA-B*51:01和B*51:08存在两个主要的亚肽区，一个在P1具有Pro2和疏水残基，另一个在1位具有富集的Ala2和Asp。在这里，我们对B7超型分子提供的肽体进行了荟萃分析，以研究不同同种型中亚肽的存在。几个同种型在P2处存在Pro或另一个残基时呈现不同的亚感受子。除HLA-B*54:01外，Ala2亚肽基优选Asp1，其中具有Ala2的配体含有Glu1。序列比对和晶体结构的分析使我们能够提出MHC重链的位置45和67与亚感受蛋白的存在相关。破译亚感受子存在背后的原理可以提高我们对其他MHC-I分子中抗原呈递的理解。运行标题：HLA-B7超型亚感受子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cellular immunology 生物-免疫学

CiteScore

8.20

自引率

2.30%

发文量

102

审稿时长

30 days

期刊介绍： Cellular Immunology publishes original investigations concerned with the immunological activities of cells in experimental or clinical situations. The scope of the journal encompasses the broad area of in vitro and in vivo studies of cellular immune responses. Purely clinical descriptive studies are not considered. Research Areas include: • Antigen receptor sites • Autoimmunity • Delayed-type hypersensitivity or cellular immunity • Immunologic deficiency states and their reconstitution • Immunologic surveillance and tumor immunity • Immunomodulation • Immunotherapy • Lymphokines and cytokines • Nonantibody immunity • Parasite immunology • Resistance to intracellular microbial and viral infection • Thymus and lymphocyte immunobiology • Transplantation immunology • Tumor immunity.